Charles Schwab
TTNP

Charles Schwab’s Titan Pharmaceuticals TTNP Stock Holding History

Charles Schwab’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-8
Closed -$100K – 3139
2017
Q1 		$100K Hold
8
– – ﹤0.01% 3018
2016
Q4 		$121K Hold
8
– – ﹤0.01% 3029
2016
Q3 		$177K Hold
8
– – ﹤0.01% 2938
2016
Q2 		$165K Buy
+8
New +$170K ﹤0.01% 2992

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MERSOM
Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $74.8M AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Charles Schwab's TTNP Position: Q2 2017 in Review

Charles Schwab sold out of Titan Pharmaceuticals (TTNP) in Q2 2017, closing a stake of 8 shares — an estimated $100K sold.

Charles Schwab first reported a position in TTNP in Q2 2016 and held it in 4 quarters. The position peaked at $177K in Q3 2016. 35 funds tracked by Wall St. Rank hold TTNP as of Q2 2017.

  • Charles Schwab reported no remaining Titan Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Charles Schwab sold 8 Titan Pharmaceuticals shares in Q2 2017, an estimated $100K.
  • Charles Schwab first reported a position in Titan Pharmaceuticals in Q2 2016 and held it in 4 quarters.
  • Charles Schwab's Titan Pharmaceuticals position peaked at $177K in Q3 2016.
  • 35 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2017.

Based on Charles Schwab's 13F filing for Q2 2017, filed 2 Aug 2017.